Effect of trastuzumab interchain disulfide bond cleavage on Fcγ receptor binding and antibody-dependent tumour cell phagocytosis

J Biochem. 2016 Jan;159(1):67-76. doi: 10.1093/jb/mvv074. Epub 2015 Aug 8.

Abstract

The Fc domain of human IgG1 binds to Fcγ receptors (FcγRs) to induce effector functions such as phagocytosis. There are four interchain disulfide bonds between the H and L chains. In this study, the disulfide bonds within the IgG1 trastuzumab (TRA), which is specific for HER2, were cleaved by mild S-sulfonation or by mild reduction followed by S-alkylation with three different reagents. The cleavage did not change the binding activities of TRA to HER2-bearing SK-BR-3 cells. The binding activities of TRA to FcγRIIA and FcγRIIB were greatly enhanced by modification with mild reduction and S-alkylation with ICH2CONH2 or N-(4-aminophenyl) maleimide, while the binding activities of TRA to FcγRI and FcγRIIIA were decreased by any of the four modifications. However, the interchain disulfide bond cleavage by the different modifications did not change the antibody-dependent cell-mediated phagocytosis (ADCP) of SK-BR-3 cells by activated THP-1 cells. The order of FcγR expression levels on the THP-1 cells was FcγRII > FcγRI > FcγRIII and ADCP was inhibited by blocking antibodies against FcγRI and FcγRII. These results imply that the effect of the interchain disulfide bond cleavage on FcγRs binding and ADCP is dependent on modifications of the cysteine residues and the FcγR isotypes.

Keywords: Fcγ receptors; IgG1; interchain disulfide bonds; phagocytosis; trastuzumab.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alkylation
  • Antibody Affinity
  • Antibody-Dependent Cell Cytotoxicity*
  • Antineoplastic Agents / chemistry*
  • Antineoplastic Agents / immunology
  • Antineoplastic Agents / therapeutic use
  • Cell Line, Tumor
  • Cytophagocytosis*
  • Humans
  • Immunoglobulin G / chemistry
  • Immunoglobulin G / immunology
  • Iodoacetamide / chemistry
  • Maleimides / chemistry
  • Neoplasms / drug therapy
  • Neoplasms / immunology*
  • Protein Structure, Secondary
  • Receptor, ErbB-2 / metabolism
  • Receptors, IgG / immunology*
  • Trastuzumab / chemistry*
  • Trastuzumab / immunology
  • Trastuzumab / therapeutic use

Substances

  • Antineoplastic Agents
  • Immunoglobulin G
  • Maleimides
  • Receptors, IgG
  • N-(4-aminophenyl)maleimide
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Trastuzumab
  • Iodoacetamide